Issued 2026-08-13 at $14.66 · now $14.39 (2026-08-13, −1.8% since)
Based on its own history, a month from the 2026-08-13 close, DSGN has typically landed between $10.20 and $20.32 — a range of −30.5% to +38.6% from the issuance price $14.66.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,330 overlapping 1 month windows · 2021-03-26 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($14.66) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where DSGN has typically landed a month from the 2026-08-13 close of $14.66 — the range is history, not a prediction.
- now $14.39 (-1.8%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $15.11 (+3.1%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $12.86–$17.36
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $10.2–$20.32
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2023-07-25 | −71.8% | −71.8% | +12.0% |
| 2023-07-26 | −71.6% | −72.0% | +11.1% |
| 2023-07-21 | −71.6% | −72.1% | +10.6% |
| 3 best | |||
| 2024-06-26 | +62.5% | −1.2% | +62.5% |
| 2024-07-02 | +57.8% | −0.3% | +64.1% |
| 2025-11-04 | +57.4% | +0.0% | +57.4% |
1,330 overlapping windows · 2021-03-26 – 2026-08-13 · not cherry-picked
Pending catalysts
- September 2026 — Trial primary completion: Phase 2 primary completion: DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy (source, as of 2026-08-14)
- December 2026 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.